What Is DSIP and How Does It Work
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide first isolated from the venous blood of rabbits in a sleep-deprived state during research in the early 1970s. It was named for its originally observed association with delta-wave (slow-wave) sleep. Decades later, its mechanism remains only partially understood - one 2006 review of the literature described it plainly as "a still unresolved riddle."
Proposed mechanisms include modulation of somatostatin release through a dopaminergic pathway, and broader effects on neurotransmitter systems including serotonin, glutamate, dopamine, and melatonin. DSIP has also been studied for effects outside of sleep architecture, including thermoregulation, heart rate, pain threshold, and - the basis for interest in cortisol normalization - modulation of the hypothalamic-pituitary-adrenal axis. None of these mechanisms are fully settled; DSIP is one of the more mechanistically ambiguous compounds in the research-peptide space.
Research Dosing
There is no clinically validated human dosing protocol for DSIP. The figures below combine what controlled human trials used with what is commonly cited in research-community protocols - these are not equivalent sources, and neither constitutes medical guidance.
| Source | Dose | Frequency | Route |
|---|---|---|---|
| Early controlled human trials | 25 nmol/kg | Single infusion (trial setting) | IV infusion |
| Commonly cited research-community range | ~100–300mcg (hedged - not a validated clinical dose) | Once nightly, before sleep | SubQ injection |
Context: The original human trials used precise IV infusions in a supervised clinical setting, timed to measure acute sleep pressure. The subcutaneous nightly dosing convention seen in research-community protocols has not been validated in a controlled trial and should be treated as an unverified community figure rather than an established dose.
Regulatory Status
DSIP is not an FDA-approved drug and is not currently listed in the FDA's 503A bulk drug substances list (21 CFR 216.23). As of mid-2026, DSIP (referred to in FDA proceedings by the name emideltide) was reviewed by the agency's Pharmacy Compounding Advisory Committee, which issued a nonbinding but unfavorable recommendation against including it as an approved bulk substance for compounding pharmacies - a signal that regulatory scrutiny on this compound is, if anything, tightening rather than loosening. Products sold as "DSIP" - including the one carried in the BioStackIQ shop - are marketed and sold as research chemicals for laboratory and research use only, not for human consumption. Consult a qualified healthcare provider before considering any research compound protocol.
What Research Shows
Human data on DSIP is older and more limited than for many peptides in this category, dating mostly to the late 1970s through early 1990s. A controlled study of intravenous DSIP in healthy volunteers reported an immediate sense of sleep pressure and a measurable increase in subsequent sleep within the following hours, along with some delayed effects on the following night's sleep architecture. However, a separate double-blind trial in patients with chronic insomnia found that short-term DSIP treatment was not likely to provide major therapeutic benefit. Reviewers of the broader literature have concluded that DSIP's overall physiological role remains unresolved rather than firmly established.
For a broader look at how sleep-support compounds fit into a research protocol, see the peptide stack beginner's guide.